AstraZeneca PLC (AZN) and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership
6/17/2013 7:09:16 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AstraZeneca: MedImmune, AstraZeneca’s Biologics Arm, and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)-- Regulatory News: AstraZeneca (AZN.ST)(AZN.L) today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.
EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1. EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis. NGM has established a proprietary platform capable of isolating and analysing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases.
MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialisation of compounds resulting from the collaboration.
“We believe that hormones found in the gastrointestinal tract can play an important role in resolving diabetes after bariatric surgery. Through NGM’s innovative research in metabolic disease, we believe our collaboration could lead to potential innovative medicines for diabetes and obesity that will make a difference in patients’ lives,” said Cristina Rondinone, Ph.D., Head of Cardiovascular and Metabolic Disease Innovative Medicines Unit, MedImmune. “Our partnership with NGM complements AstraZeneca’s existing small molecule and biologics portfolio in cardiovascular and metabolic disease, one of our core therapy areas.”
Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration. If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.
“We are excited to enter into this strategic partnership with MedImmune as it represents a unique opportunity to maximise the full complement of novel hormones secreted by these EECs for drug discovery purposes,” said Jin-Long Chen, Ph.D., founder, president and chief scientific officer of NGM. “Together, NGM and MedImmune will build upon the culture of scientific excellence at both organisations. With MedImmune’s deep biologics and development expertise, we are confident that we will further enrich the pipeline of therapies for the treatment of diabetes and obesity.”
About NGM Biopharmaceuticals, Inc.
Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases. The Company is focused on discovering the next generation of therapeutics that will fundamentally change the treatment paradigm for the growing population of diabetes and obesity patients worldwide. NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals and JDRF. For more information, please visit the company’s website at www.ngmbio.com.
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
This information was brought to you by Cision http://news.cision.com
Esra Erkal-Paler, +44 20 7604 8030 (UK/Global)
Vanessa Rhodes, +44 20 7604 8037 (UK/Global)
Ayesha Bharmal, +44 20 7604 8034 (UK/Global)
Tracy Rossin, +1 (301) 398-1468 (US/MedImmune)
Jacob Lund, +46 8 553 260 20 (Sweden)
James Ward-Lilley, +44 20 7604 8122, mob: +44 7785 432613
Karl Hård, +44 20 7604 8123, mob: +44 7789 654364
Colleen Proctor, + 1 302 886 1842, mob: +1 302 357 4882
Ed Seage, + 1 302 886 4065, mob: +1 302 373 1361
Help employers find you! Check out all the jobs and post your resume.